NHS England updates CDF List

NHS England updates CDF List

NHS England has updated the Cancer Drugs Fund List. The latest version (v1.339) was uploaded to the NHS England Website on Thursday 19, December 2024.

The following changes have been introduced:

Elacestrant monotherapy (ELAC1)

For the treatment of oestrogen receptor- positive, HER2-negative, locally advanced or metastatic breast cancer in patients previously treated with at least 12 calendar months of therapy with a CDK4/6 inhibitor-based combination where the following criteria have been met

Recommended for routine commissioning, receiving CDF interim funding

Alectinib (ALE2)

Alectinib monotherapy for adjuvant treatment in adults after complete tumour resection in patients with UICC/AJCC 8th TNM edition stage IB (4cm only) or IIA or IIB or IIIA or N2 only IIIB non-small cell lung cancer whose tumours have an ALK gene rearrangement where the following criteria have been met

Title and treatment criterion (#4) updated

Apalutamide in combination with androgen deprivation therapy (ADT) (APA2)

For the treatment of patients with newly diagnosed metastatic hormone-sensitive prostate cancer who are ineligible for chemotherapy with docetaxel where the following criteria have been met

Treatment criterion (#8) updated

Enzalutamide in combination with androgen deprivation therapy (ADT) (ENZ3)

For the treatment of patients with newly diagnosed metastatic hormone-sensitive prostate cancer where the following criteria have been met

Treatment criterion (#7) updated